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Rift Valley Fever in
Goats, Cameroon 
To the Editor: Rift Valley fever
(RVF) is caused by an RNA virus
(Phlebovirus, Bunyaviridae), which is
carried by mosquito vectors (1). In
nature, it is only known in Africa and
the Arabian Peninsula. In the central
African region, RVF has been report-
ed in humans and livestock in the
savanna of northern Cameroon and
Chad (2,3) and from forests in the
Central African Republic (4). Human
epidemics are sometimes preceded by
an increase in RVF virus (RVFV)
prevalence in domestic ruminants,
which manifests as increased abor-
tions and high neonatal deaths (3).
Human epidemics can have serious
health implications, as demonstrated
by the most recent outbreaks in Kenya
in 1997 and 1998 (5) and Saudi
Arabia in 2001 (6). 
In June 2003, 14 goats from an
urban market in Yaoundé (3.9°N,
11.5ºE), Cameroon, and 36 goats from
3 adjacent villages in tropical lowland
rainforest ≈80 km south of Mvangan
(2.4ºN, 11.8ºE), Cameroon, were
sampled. The goats in the rural vil-
lages were bred locally and allowed to
roam freely throughout the villages.
No vaccinations had been given to
goats in the rural sites. Goats in the
urban market in Yaoundé generally
originated in northern Cameroon and
had been transported by train to
Yaoundé. Owners did not report high
levels of abortion or high neonatal
deaths.
Jugular blood was collected in a 5-
mL dry Vacutainer tube and cen-
trifuged within 48 hours of collection.
The frozen sera were shipped on ice to
the Onderstepoort Veterinary Institute,
the United Nations Food and
Agriculture Organization reference
laboratory for RVFV. An indirect
enzyme-linked immunosorbent assay
(I-ELISA) was used to detect RVFV
immunoglobulin G (IgG) antibodies in
26 samples. In this assay, optical den-
sity readings were converted to a per-
centage of high-positive control serum
(PP) and positive samples were those
with PP >10. These samples were fur-
ther tested with RVFV hemagglutina-
tion inhibition (HI), and samples with
titers >20 were considered seroposi-
tive (7). Positive I-ELISAand HI sam-
ples were confirmed by using a serum
neutralization (SN) assay (7,8). Asam-
ple was considered seropositive when
it had an SN titer of >4, determined
during experiments on laboratory-
injected sheep (7–9) and testing of
wild and domestic African ruminants
(7). The SN assay has been shown to
be highly specific; cross-reactivity
with other viruses from the family
Bunyaviridae is not likely (9). 
Of the 26 goat samples tested for
RVFV, 6 tested positive to RVFV
(Table). Samples from 5 goats from
the rural villages and 1 from the urban
market had RVFV IgG PP >10.
Samples from 2 goats from the rural
villages had high RVFV HI titers (320
and 5,120). Three of the 6 samples
from the rural villages with high IgG
PP and HI titers had elevated neutral-
ization titers (>4).
The results indicate for the first
time that RVFV is present in forests of
southern Cameroon. Given the ages of
the seropositive goats (2, 3, and 4.5
years), transmission of the virus
occurred recently.
In savanna goat herds in northern
Cameroon, RVFV IgG prevalence has
been reported at 9% to 20% (2). To
determine prevalence of RVFV in
goats in southern Cameroon, more
animals need to be sampled; the small
sample size and isolation of the few
rural villages are unrepresentative.
The presence of RVFV antibodies
in domestic animals suggests that this
virus may also be circulating in
human populations, despite the
absence of reports. A study of 21 per-
sons in Ngoïla in southern Cameroon
found no RVFV antibodies during a
bloody diarrhea epidemic in 1998
(10,4); however, testing facilities for
RVFV are not available in Cameroon,
and the general population and health-
care providers have limited awareness
of the virus and associated disease.
Central African forests have a high
diversity of forest ungulates (>10
species), and RVFV has been reported
from a number of wild African ungu-
lates (7). The potential for exchange of
RVFV and other pathogens between
goats and wild ungulates could have
substantial effects on animal produc-
tion and on the conservation of wild
species, some of which are considered
near-threatened. Livestock disease
surveillance can play a role not only in
assessing the distribution of livestock
pathogens but also in monitoring dis-
ease emergence.
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HIV-1 CRF07_BC
Infections,
Injecting Drug
Users, Taiwan 
To the Editor: To date, Taiwan’s
human immunodeficiency virus type
1 (HIV-1) epidemic has primarily
spread via sexual contact. The sub-
type B and circulating recombinant
form (CRF) 01_AE account for >95%
of all infections (1). However, since
2003 Taiwan has experienced a major
outbreak of CRF07_BC among inject-
ing drug users (IDUs).
The first wave of HIV-1 infections
in Taiwan can be traced to the early
1980s, when a group of hemophilia
patients received imported HIV-1-
contaminated antihemophilia medica-
tions. By the time these medications
had been replaced by heat-treated fac-
tor VIII concentrates, at least 53
patients had contracted HIV-1 infec-
tions (2). According to Taiwan’s
Center for Disease Control (CDC),
HIV infections have been diagnosed
in 9,229 persons (including 523 for-
eigners) as of July 31, 2005 (3). The
number of persons living with HIV-
1/AIDS has increased rapidly in the
past few years, with a 77% increase in
2004, compared to 11% in 2003
(online Table, available at http://
www.cdc.gov/ncidod/EID/vol12no04
/05-0762.htm#table). According to
the results of a risk factor analysis of
people living with HIV-1/AIDS
reported to the Taiwan CDC, the pro-
portion of IDUs increased from 1.7%
(13/773) in 2002 to 8.1% (70/861) in
2003 to 30.3% (462/1,521) in 2004
(online Table). The Taiwan CDC
received reports of 1,241 IDUs diag-
nosed with HIV-1 infections from
January 1 to July 31, 2005; these
account for >75% of all reported HIV-
1 infections in 2005 (3). The evidence
points to an explosive epidemic of
HIV-1 infections among IDUs in
Taiwan since 2003, with no indication
of a slowdown.
Taiwan has ≈60,000 IDUs (1).
According to the Republic of China
Ministry of Justice, the number of
incarcerated drug offenders increased
from 5,988 in 2003 to 9,303 in 2004;
the rate of HIV-1 seropositive inmates
increased from 13.3/100,000 in 2002
to 56.8/100,000 in 2004 (Y-M. Wu,
Ministry of Justice, pers. comm.).
Since all inmates are routinely tested
for HIV-1 in detention centers, and all
infected inmates are separated from
HIV-1–seronegative inmates, the
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